ArticleSurgical endoscopy2026
Celiac axis stenosis as an overlooked extrapancreatic predictor of fistula after pancreaticoduodenectomy.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCeliac axis stenosis (CAS) has been historically underappreciated in risk stratification for clinically relevant postoperative pancreatic fistula (CRPOPF). In this study, we aimed to investigate the role of CAS as an independent and clinically meaningful extrapancreatic predictor and assess its incremental value in established predictive models. MATERIALS AND
methodsOverall, 1214 consecutive pancreaticoduodenectomies were conducted between January 2021 and December 2023. Patients with available preoperative abdominal contrast-enhanced computed tomography images were identified for this outcome-based retrospective cohort study. The CAS rate was assessed retrospectively using sagittal reconstruction of arterial phases and classified into no (< 30%), mild (30%-<50%), and severe (≥ 50%) stenosis. Associations between CAS and CRPOPF were analyzed using univariable and multivariable logistic regression. An extended prediction model incorporating CAS was developed based on the Alternative Fistula Risk Score (a-FRS) to evaluate the incremental predictive value of CAS.
resultsIn total, 887 patients were eligible, of whom 228 (25.7%) had CAS. CAS significantly increased the risk of CRPOPF (p < 0.001) and remained an independent predictor (odds ratio: 3.134, 95% confidence interval: 2.153-4.564, p < 0.001), along with soft pancreatic texture, smaller main pancreatic duct, higher body mass index, and bile duct lesions. However, further stratification of stenosis into mild and severe categories did not reveal significant differences in CRPOPF rates, indicating an "all-or-none" threshold effect. Incorporating CAS into the a-FRS model yielded statistically significant but modest improvements in discrimination (p = 0.005), net benefit, and overall model fit (p < 0.001).
conclusionCAS is an overlooked extrapancreatic predictor of CRPOPF. Its incorporation provided modest additional information within an established risk stratification framework. Routine reporting and preoperative intervention for CAS before pancreaticoduodenectomy may be informative and its integration into future studies may help predict and prevent CRPOPF. These results require further validation with multicenter prospective data.
Indexed as
Identifiers
42675304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.